NEW YORK, Feb 6 – Protogene of Menlo Park, Calif., said Tuesday it had entered a collaborative agreement with the University Health Network of Toronto to evaluate its customizable oligonucleotide DNA microarrays.
“This relationship enables us to evaluate Protogene’s high quality customized arrays,” Bob McArthur, director of technology transfer and research business development at the network, said in a statement. “In the future, broader access to Protogene’s microarrays may further expand the collection of tools that we can offer to our customers."
Financial terms of the deal were not disclosed.
The University Health Network, a network of teaching hospitals with about 1,500 biomedical researchers, currently manufactures cDNA and oligonucleotide microarrays at its microarray center and sells them to researchers around the world.
Protogene, a privately held company with 90 employees, makes custom oligonucleotide DNA microarrays using a patented surface tension array technology, in situ synthesis of oligonucleotides, and high-speed inkjet printing.
Recently, Protogene announced that it would co-market its microarrays with Silicon Genetics’ GeneSpring expression analysis software. The company has also signed a deal with Sequenom to work together to combine their technologies into a silicon-based diagnostic chip.